Navigation Links
ThromboGenics N.V.: Business Update
Date:11/6/2008

chris.buyse@thrombogenics.com .

Citigate Dewe Rogerson:

Amber Bielecka/ David Dible/ Nina Enegren, Tel: +44(0)207-638-95-71,

amber.bielecka@citigatedr.co.uk

About ThromboGenics

ThromboGenics is a biotechnology company focused on the discovery and development of biopharmaceuticals for the treatment of eye disease, vascular disease and cancer. The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent in stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Dublin, Ireland and New York, U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reaso
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ThromboGenics Announces Half Year Results 2008
2. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
3. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
4. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
5. ThromboGenics N.V. - Business Update
6. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
7. ThromboGenics Announces 2007 Full Year Results
8. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
9. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
10. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
11. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... and Hershey, PA (PRWEB) December 19, 2014 ... BJCT), a leading developer and manufacturer of needle-free ... into an agreement with Immunomic Therapeutics, Inc. (“ITI”) ... needle-free injection device with its LAMP™ vaccine platform. ... option for an exclusive Worldwide license to the ...
(Date:12/19/2014)... EVANSTON, Ill. , Dec. 19, 2014 ... to develop novel drugs for diseases of the central ... Ph.D., president and chief executive officer, will present at ... Dr. Riedel,s presentation will take place at 3:00 p.m. ... St. Francis in San Francisco, Calif. ...
(Date:12/19/2014)... Mass. , Dec. 19, 2014 Decision ... market will grow at a 12 percent compound annual ... result of the aging population and the increasing adoption ... Latin America will also spur demand for ... of dental implant and periodontal treatments. Other ...
(Date:12/19/2014)... (PRWEB) December 18, 2014 Today, ... locate its pilot production facility and future company ... and produce innovative new materials that safely and ... not only because of its historic, strong support ... efforts to attract leading edge, technology-based companies such ...
Breaking Biology Technology:Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 2Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 4
... May 19, 2011 Ardea Biosciences, Inc. (Nasdaq: ... completed, multi-center, Phase 1, monotherapy, dose-escalation study of BAY ... an Oral Abstract Session at the 2011 American Society ... on Sunday, June 5, 2011. Presentation ...
... 19, 2011 Isis Pharmaceuticals, Inc. (NASDAQ: ... $5 million milestone payment from GlaxoSmithKline (GSK) related to ... ISIS-TTRRx.  ISIS-TTRRx is designed to treat transthyretin amyloidosis, a ... of peripheral nerve and/or heart tissues . ISIS-TTRRx ...
... YORK, May 19, 2011 Reportlinker.com ... report is available in its catalogue: ... (MEMs) Devices Industry ... report analyzes the worldwide markets for ...
Cached Biology Technology:Ardea Biosciences Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at 2011 American Society of Clinical Oncology Annual Meeting 2Ardea Biosciences Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at 2011 American Society of Clinical Oncology Annual Meeting 3Isis Initiates Phase 1 Study of ISIS-TTRRx and Earns $5 Million Milestone Payment From GlaxoSmithKline 2Isis Initiates Phase 1 Study of ISIS-TTRRx and Earns $5 Million Milestone Payment From GlaxoSmithKline 3Isis Initiates Phase 1 Study of ISIS-TTRRx and Earns $5 Million Milestone Payment From GlaxoSmithKline 4Global Micro-Electromechanical Systems (MEMs) Devices Industry 2Global Micro-Electromechanical Systems (MEMs) Devices Industry 3Global Micro-Electromechanical Systems (MEMs) Devices Industry 4Global Micro-Electromechanical Systems (MEMs) Devices Industry 5Global Micro-Electromechanical Systems (MEMs) Devices Industry 6Global Micro-Electromechanical Systems (MEMs) Devices Industry 7Global Micro-Electromechanical Systems (MEMs) Devices Industry 8Global Micro-Electromechanical Systems (MEMs) Devices Industry 9Global Micro-Electromechanical Systems (MEMs) Devices Industry 10Global Micro-Electromechanical Systems (MEMs) Devices Industry 11Global Micro-Electromechanical Systems (MEMs) Devices Industry 12Global Micro-Electromechanical Systems (MEMs) Devices Industry 13Global Micro-Electromechanical Systems (MEMs) Devices Industry 14Global Micro-Electromechanical Systems (MEMs) Devices Industry 15Global Micro-Electromechanical Systems (MEMs) Devices Industry 16Global Micro-Electromechanical Systems (MEMs) Devices Industry 17Global Micro-Electromechanical Systems (MEMs) Devices Industry 18Global Micro-Electromechanical Systems (MEMs) Devices Industry 19Global Micro-Electromechanical Systems (MEMs) Devices Industry 20Global Micro-Electromechanical Systems (MEMs) Devices Industry 21Global Micro-Electromechanical Systems (MEMs) Devices Industry 22Global Micro-Electromechanical Systems (MEMs) Devices Industry 23Global Micro-Electromechanical Systems (MEMs) Devices Industry 24
(Date:12/17/2014)... 15, 2014 Research and Markets ... the "Samsung Galaxy S5 - Home Button ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... sensing technology than the iPhone 5S, Samsung introduces ... its product. The Galaxy S5 home ...
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ... "Global Chemical Sensor Market 2015-2019" report to ... One major trend upcoming in ... sensors in biomedical applications. Chemical sensors help in ... diagnosis during surgical procedures. The Global Chemical Sensor ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... species in streams begins to occur at the initial stages ... USGS. The study found that streams are more sensitive to ... of waterways as fragile organisms, and yet that is exactly ... telling us," said USGS Director Marcia McNutt. "Streams are more ...
... This release is available in French . ... according to a review lead by Gabriel Shapiro of the ... Mother and Child Hospital. Women are at the highest risk ... a child may trigger a depressive episode in vulnerable women. ...
... at the National Institute of Standards and Technology (NIST) ... nanotubes (SWCNTs) may help protect DNA molecules from damage ... process in which a reactive chemical removes electrons from ... cells. More studies are needed to see if the ...
Cached Biology News:Streams show signs of degradation at earliest stages of urban development 2NIST study suggests carbon nanotubes may protect DNA from oxidation 2
This free-standing laminar flow hood provides a vertical flow of HEPA-filtered air to create a clean processing area. It includes a fluorescent light and motorized sliding shield. Options include wor...
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: rack ...
... GX-1000 3-D Shaker , ,Product Information ... of the GyroTwister GX-1000 is extremely efficient, ... general mixing as well as staining gels, ... continuously adjustable across a broad range. A ...
...
Biology Products: